pegylation


Also found in: Dictionary, Wikipedia.

pegylation

(pĕg′ĭ-lā′-shŭn)
The chemical linking of a drug (e.g., interferon) to polyethylene glycol. Pegylation increases the half-life of interferon.
References in periodicals archive ?
Two PEGylation methods were also compared to distinguish the most stable product in various conditions: these were maleimide-PEGylation and cyanuric chloride PEGylation.
PolyTherics has developed and patented an innovative approach to PEGylation, known as TheraPEG, to prolong the half-life of proteins for therapeutic application.
Nektar and Affymax entered into a partnership in 2004 under which Nektar provides Affymax with its Advanced PEGylation Technology to develop Hematide.
and Inhale announced a broad strategic alliance that includes a collaboration to develop three products using Inhale's Inhance(TM) pulmonary delivery platform or SEDS(TM) supercritical fluids platform; an agreement making Inhale solely responsible for licensing Enzon's PEG patents, which includes over 40 US patents; an option for Enzon to license Inhale's PEGylation patents; and an agreement to explore the development of non-invasive delivery of single-chain antibody products via the pulmonary route.
MVP also announced the publication of an invited scientific report, titled "Next-Generation PEGylation Enables Reduced Immunoreactivity of PEG-Protein Conjugates," inthe June 2012 issue of Drug Development & Delivery.
Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms, has today reported its financial results for the first half of 2012.
PolyTherics applied its HiPEG site-specific PEGylation technology to interferon alpha to produce HiPEG IFN [alpha]-2a, which in a preclinical study showed eight-fold higher activity than a marketed PEGylated interferon in vitro, and a comparable half-life.
Zealand Pharma has developed a number of peptide-based therapeutic candidates which are amenable to PEGylation, while PolyTherics has capabilities in improving the duration of action of biotherapeutics using targeted PEGylation technologies.
Targeted attachment of PEG to growth hormone results in a homogeneously modified protein with high biological activity and overcomes the problems of product heterogeneity and loss of activity that occurs when growth hormone is modified using non-targeted PEGylation technologies.
PEGylation slows elimination from the body, thereby improving half-life and potentially reducing drug treatment frequency, decreasing side effects and improving patient compliance.
The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.